This is an aggregated industry headline. Read the full story at FierceBiotech →
Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS
Roche's investigational KRAS G12C inhibitor has beaten Amgen's Lumakras and Bristol Myers Squibb's Krazati in a phase 3 trial, furthering its ambitions to establish divarasib as a new standard of care.
By FierceBiotech
· Jul 3, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The ad uses hand-crafted puppets to portray sight-based frustrations for those with presbyopia, a common condi…
The WeekBriefing
CMS is again proposing reduced Medicare payments for 340B drugs, reopening a long fight over hospital margins …
The WeekSTAT News ↗
Lawmakers step into a dispute between Eli Lilly and hospitals about the 340b drug discount program.…